Revolution Medicines Begins Phase 3 RASolute 303 Trial Treatments To Evaluate Daraxonrasib For Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Benzinga Newsdesk www.benzinga.com Positive 84.6%

Neg 0% Neu 0% Pos 84.6%

Comments

No comments yet. Be the first!